Asad Balal

🔬 Illumina announces $750 million credit agreement with J.P. Morgan 🔬 Illumina, a leading player in the genomic sequencing industry, has just announced a significant financial milestone. The company has secured a $750 million credit agreement with JP Morgan, aimed at supporting the divestment of its subsidiary, GRAIL. This strategic financial move is expected to strengthen Illumina’s financial position and facilitate the growth and development of its core genomic technologies. Grail, known for its groundbreaking early cancer detection technology, will benefit from this divestment as it continues to innovate and expand its impact on healthcare. This is great news from Illumina and JP Morgan, demonstrating strong confidence in the future of genomic health and personalized medicine. #genomics #Illumina #grail #genomicsequencing #biotech

13

AbbVie’s acquisition of LABP is now complete. The NImmune Biopharma founding team built Landos from the ground up into a public biotech company with $600 million market capitalization to accelerate the development of I&I therapeutics. Our groundbreaking immunology research on novel mechanisms of action, such as LANCL2 and NLRX1, and our talented team have led to the development of first-in-class therapeutics for ulcerative colitis and Crohn’s disease, including omilancor, NX-13, and NIM-1324. ABBV will now carry on our work and mission to develop the novel potential of Phase 2 NLRX1-targeted therapeutics like NX-13, while at NImmune we will continue our mission to develop the better-characterized, later stage, clinically validated Phase 3 LANCL2-targeted therapeutic franchise. This includes omilancor, a best-in-class Phase 3 precision therapeutic with a multipronged mechanism of action that regulates immunometabolism in immune cells while restoring epithelial barrier function in IBD. NImmune Biopharma, Inc. is built to boldly advance the next wave of innovative first-in-class and best-in-class treatments for inflammatory and autoimmune diseases that meaningfully improve patient outcomes. PR of the news: https://lnkd.in/gpHF3_sP Learn more about NImmune here: https://nimmunebio.com/   #Biopharma #Immunology #DrugDevelopment #UlcerativeColitis #Crohns

8

That’s a wrap on American Society of Clinical Oncology (ASCO) 2024!   Looking for a quick recap? Check out our latest blog “Top News from Biggest Players at ASCO 2024” to see a summary of key data and takeaways.   https://lnkd.in/eFZm_kjy   #ASCO24 #Oncology #AdelphiResearch #MarketResearch

62

Case Study: Creative Recruitment Strategies for a New Industry. This case study highlights the success of recruiting beyond traditional industries, utilizing competitor research and targeted outreach to identify individuals with the desired skill set. Eastridge Life Science SMEs Drew Rennie and Grace Irvine share insights into recruiting for scientific roles. https://hubs.ly/Q02tvS030

15

🎉🌟 Hats off to Ben Cadieux, Executive Director at Arvinas (Former), currently in Cygnus Therapeutics, for his outstanding role as Chairperson for Day 1 at the 20th BioPharma Clinical Trials Nexus Event! 📣His adept management ensured the smooth flow of discussions & significantly contributed to the success of this event. Ben also shared insightful perspectives on "Precision Medicine in Neurology: A Medical Affairs Perspective" 🌟Thank you Ben for guiding us through a world of knowledge and innovation. Don't miss out on his exceptional insights! #Clinicaltrials #20thBioPharma #Procurementdirect #Medicalaffairs #Neurology #ClinicalOperations #NexusConference #Medicine #

22

“GLP-1 is projected to be a $100 billion market by 2030, indicating a substantial increase in syringe consumption.” says Cory Lewis, CEO, President, and Founder of INCOG BioPharma Services. Ahead of CDMO Live this week, Cory spoke to the PharmaSource podcast about why strategic thinking is crucial for success in this fast-moving landscape. 🎧 Listen to the full interview: https://lnkd.in/esj9YYAv “We’re not just planning for the immediate needs but looking one, two, even three years ahead. With our second and third production lines in the pipeline, we’re preparing for the long-term demands of the market.” Founded in June 2020, INCOG has secured FDA-approval and now establishes itself as a new force in contract manufacturing with a focus on sterile injectables. Despite the company only being four years old, INCOG’s leadership team brings decades of industry experience.  Cory says he has brought the ‘band back together’ by reuniting seasoned professionals to create a tier-one contract manufacturing organisation. INCOG’s investments in vial, syringe, and cartridge filling capabilities are “just the beginning” he says. “We’re also expanding into quality control, lab stability services, and eventually, auto-injector device assembly and final packaging. Our long-term site master plan outlines our ambition to not only enhance filling capacity, but also integrate additional business units to support commercial packaging and device assembly.” “Our first FDA approval, achieved less than eighteen months after production began, is a testament to our operational and quality excellence. This milestone was marked by an eight-day inspection with zero observations, a rare accomplishment in our industry.” --- Join INCOG at #CDMOLive this Thursday, for an exclusive online event dedicated to accelerating, optimising and decarbonising contract manufacturing. 👉 Register here for your free ticket: https://lnkd.in/eNB_vxzm #CDMO #GLP1

25

🎉 Get ready to unlock the keys to success in the small biopharma sector with Jerry W., Associate Director at Ascentage Pharma, LIVE at the 20th Biopharma Clinical Trials Nexus Conference! 🌟 Join Jerry as he delves into the dynamic world of "Effectively Steering Your Clinical Trials for Success in the Small Biopharma Sector." 🚀🔬 Dive deep into actionable strategies, insider tips, and real-world case studies tailored specifically for small biopharma innovators. 💡 Don't miss this exclusive opportunity to learn from one of the industry's brightest minds and gain the competitive edge you need to drive your clinical trials to success. 🎤 #BiopharmaClinicalTrials #Innovation #SuccessSecrets #SanDiegoConference

28

1 Comment

Here's how Artificial Intelligence is changing the game for QPs 👀 What do you think? #BiotechJobs #PharmaRecruitment #QualityAssurance #LifeSciences #HealthcareRecruitment #BiotechCareers

3

It is day one of the Cell and Gene Therapy Pricing and Reimbursement Summit agenda. Catch up with Tom Smith and Tharshan Umakanthan to find out how we can support you to build the optimum environment for cell and gene therapy assets in complex markets #CellandGeneTherapy #PricingReimbursement #MarketAccess #ExpandedAccess #ExpandedAccessProgram

8

Below are some exciting new EXECUTIVE appointments which have taken place recently over the last week. 👨‍🔬 👩‍🔬 Egle Therapeutics have appointed Pejvack Motlagh as their new CMO.✅ Scipher Medicine have appointed Reginald Seeto as their new CEO. ✅ CHARM Therapeutics appointed Nick Edmunds as their new CDO. ✅ Seaport Therapeutics have appointed Eric Green as their new COO. ✅ Carisma Therapeutics have appointed Eugene Kennedy their new CMO. ✅ PreludeDx have appointed Pat Whitworth as their new CMO. ✅ Araceli Biosciences have appointed Matt Beaudet as their new CEO. ✅ Ratio Therapeutics have appointed Marc Becker as their new CFO/COO. ✅ Congruence Therapeutics have appointed Michael Harvey as their new CDO. ✅ Topas Therapeutics GmbH have appointed Hugo Fry as their new CEO. ✅ Wave Life Sciences have appointed Erik Ingelsson as their new CSO. ✅ Candid Therapeutics have appointed Ken Song as their new CEO. ✅ Huge congratulations to all these incredible leaders from myself & everyone at Elixir Associates. 👏 👏 👏 #Appointments #Leaders #Executive #Congratulations #News #Elixir #Leadership #Hiring #Medical #Regulatory #Clinical #DrugDevelopment #LifeSceinces #Healthcare #Pharma #DrugDevelopment #Biotech

10

LABCORP, QUEST ISSUE Q1 EARNINGS, OFFER COMMENTS ON FDA’S LDT RULE Both clinical lab companies benefited from acquisitions of independent lab firms and hospital outreach labs BOTH LABCORP, BURLINGTON, N.C., AND QUEST DIAGNOSTICS, SECAUCUS, N.J., reported strong financial performance during the first quarter (Q1) of 2024. Base business—diagnostics excluding COVID-19 testing—jumped about 6% during Q1 as compared to base business in Q1 2023. Here is an overview of their financial results as well as key Q1 accomplishments. LABCORP: Grows Q1 Revenue 4.6%; Plans Purchase of ‘Select Assets’ of Invitae Labcorp shared these Q1 2024 financials as compared to Q1 2023 during its Q1 conference call on Apr. 25, 2024: Revenue grew 4.6% to $3.18 billion from $3.04 billion. Base business increased 6.7%. Diagnostics lab revenue was up 4.1% to $2.48 billion from $2.38 billion. Biopharma lab services revenue jumped 7.5% to $710.9 million from $661.3 million. Volume (measured by requisitions) grew 3.4%. Labcorp opened its Q1 earnings call by announcing its intent to purchase select assets of Invitae Corporation, a San Francisco-based medical genomics company. Labcorp will pay $239 million for certain Invitae assets. Labcorp expects to make about $275 million to $300 million in annual revenue as a result of the deal, which is expected to close in Q3 2024. “This transaction will advance our strategy to launch and scale specialty testing in areas such as oncology rare diseases. These are strong assets in important disease areas and strategically [correspond] with our focus... Read The Dark Report article at https://hubs.ly/Q02B4L9d0 Not already a subscriber? Sign up for a FREE 14-Day Trial at https://hubs.ly/Q02B4L6q0

2

Redx Pharma released their latest update this morning - "Redx Reports Encouraging Zamaporvint (RXC004) Phase 2 Combination Data in MSS mCRC at ESMO GI Congress Supporting Genetic Selection Hypothesis in Hard-to-Treat GI Cancers" To read the full report, please click the link below: https://lnkd.in/e2GY6BpJ Natalie Cook, Chief Investigator for the zamaporvint Study Programme commented: “It is very encouraging to see the data returned from this signal-searching study. The indications targeted are in populations with a particularly poor prognosis and limited treatment options. Wnt inhibition has long held promise for this genetically-selected patient group and a tolerable, clinically active Porcupine inhibitor in combination with anti-PD-1 could potentially offer a new treatment option for patients with these particularly hard to treat cancers.” About Redx Pharma Limited Redx Pharma (JPJ: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted therapeutics for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis. Redx aims to progress its programmes to clinical proof of concept before evaluating options for further development and potential value creation.

7

Featured highlights from today's Efortless Update: [Clinical Trials] 「Arecor Therapeutics plc reports phase I trial success with AT278, achieving primary and secondary endpoints in Type 2 diabetes」 「Vicore Pharma AB reports phase 2a AIR trial results with 216 mL increase in FVC for buloxibutid in idiopathic pulmonary fibrosis treatment」 「Esperion and Otsuka Pharmaceutical Companies (U.S.) report phase 3 trial success with bempedoic acid showing reduction in LDL-C levels in hypercholesterolemia patients in Japan」 「Gilead Sciences reports seladelpar improves markers of cholestasis in 70% of PBC patients in ASSURE study」 「Ferring Pharmaceuticals' BEYOND trial shows 1.3 more oocytes retrieved with follitropin delta in first IVF/ICSI cycles using GnRH agonist protocol compared to antagonist protocol」 [Deals] 「Dana-Farber Cancer Institute and eFFECTOR Therapeutics, Inc. partner for zotatifin trial in ER+ endometrial and low grade serous ovarian cancers led by Dr. Panagiotis Konstantinopoulos」 [Regulatory] 「European Commission requests re-evaluation of Translarna following CHMP's negative opinion while PTC Therapeutics, Inc. suspends 2024 revenue guidance due to authorization uncertainties」 View the full newsletter contents for free via the link in the comments.

2

1 Comment

BIG NEWS! Genezen has signed an agreement to acquire uniQure’s commercial gene therapy manufacturing operations in Lexington, Massachusetts. This strategic acquisition will enable Genezen to deliver late-phase and commercial gene therapy development and manufacturing services to customers around the world. Steve Favaloro, President and Chief Executive Officer of Genezen, commented, “...This acquisition significantly enhances Genezen’s scale and differentiated capabilities, directly aligned with our mission to advance cell and gene therapies by providing top-tier, science-driven development and manufacturing solutions. We are honored to deliver these services to our current customers and the patients they serve, and are well positioned to immediately extend our support to even more customers in Lexington.” #cdmo #viralvectors #cellandgenetherapy #celltherapy #genetherapy #precisionmedicine #mergersandacquisitions #investment #finance #pharma #biotech CSL Ampersand Capital Partners https://lnkd.in/eqDDc_cf

186

15 Comments

Blackstone Life Sciences is making waves with Uniquity Bio, a new startup armed with $300M and Merck's solrikitug, set to begin Phase 2 trials for COPD and asthma. This monoclonal antibody targets TSLP, a key player in immune responses, aiming to offer best-in-class efficacy. Key Insights - 🔹 Market Potential: TSLP-targeting therapies are gaining traction, with significant room for innovation. 🔹 Investment Strategy: Blackstone’s substantial backing highlights their commitment to transformative medicines. 🔹 Competitive Landscape: Uniquity joins a competitive field with rivals like AstraZeneca, GSK, and Upstream Bio. Questions - 1. How will Uniquity Bio differentiate solrikitug from existing treatments? 2. What are the broader implications for patients with chronic inflammatory conditions? 3. How will this impact the future of immunology drug development? #Biotech #HealthcareInnovation #Investment #Pharmaceuticals #LifeSciences

3